2 September 2010

Surface Technology Systems

NO RECOMMENDATION

02/08/2002

Surface Technology Systems supplies the equipment that allows makers of micro-electro mechanical systems to scratch silicon chips. In the words of chief executive Ian Smith - 'we make large and hi-tec capital equipment that is then used to make other devices fabricated using semiconductor technology'. In a bearish trading statement, Smith said the global downturn has continued to put pressure on some of its markets throughout the world in 2002. In addition he said that first-half orders were below expectations as customers delayed their purchasing decisions. Furthermore, where orders have been won the gross margin has been affected by lower average prices for machines. He also flags up a £1.3m one-off component inventory charge for the first half. All of this means interim losses will be wider than expected when the company reports next month. Furthermore, expectations of a 2002 full-year profit will not be met, since Smith expects to make a further loss in the second half as 'adverse market conditions' continue. Back in March the group unveiled a sparkling set of annual numbers to 31 December. Sales surged 58% to £56.7m, operating profits put on 70% to £6.1m and pre-tax profits powered ahead 86% to £5.3m. House broker Rowan Dartington now expects a £6.8m pre-tax loss for 2002. The shares were issued at 138p in December 2000.

Sector: Software & Computer Services

Companies: Surface Technology

Market cap: £10.97m

PE Forecast: n/a

Share price: 35p

Subscribe today


More breaking news stories.
More extended feature articles.
And a depth of analysis you
can't find anywhere else.

Subscribe today and save 50%

VCT Report 2010

VCT Report 2010 uncovers the money available

for investment in every single VCT, helping you get one step ahead in the race to attract funding for your unquoted, AIM-listed or PLUS-quoted

company.

Order VCT Report 2010 today using this online form

Cash Shells Directory 2010

A comprehensive overview of cash shells on AIM and PLUS, companies that have become a significant feature on the market landscape. For more information and to order, click here or contact our marketing team on 020 7250 7056.

Coverage of AIM, techMARK and PLUS Markets

Informative features and research on fast-growing companies, small-cap and growth stocks, penny shares, stock market tips and share recommendations, directors' dealings, company news and analysis, new issues and upcoming IPOs.

Take control of your investments

A full year's subscription to What Investment magazine for £19.95, a whopping 58% off. Get the latest news, features and expert advice on ISAs, Investment Trusts and Funds, SIPPS, Investing for Children and much much
more. Find out more here.

The Financial Times Guide to Personal Tax

is the definitive and most up-to-date guide to completing your self-assessment tax return, making sure that you get it right and on time, and showing how you can save tax. For more information and to order, click here or contact our marketing team on 020 7250 7056.

The AIM Guide Spring 2010

The new, fully updated AIM Guide is now available to buy for only £49.95 (saving you £30).

A 'must-have' for any serious investor or professional interested in the market for young, fast-growing companies. Order your copy today Hurry, as offer ends soon!

Share recommendations and small-cap stock picks

Small-cap and growth company share recommendations on AIM- and PLUS-listed companies. Latest analysts' stock tips and advice on which are the best shares to buy on London's junior stock markets.

Popular Recommendations

Latest Recommendations

Delcam 01/09/2010

Delcam, the international seller of CAD/CAM software to the engineering, aerospace and healthcare sectors among others, is a cash-generative small-cap seeing recovery in its markets.

Antisoma 01/09/2010

Bombed-out biotech play Antisoma is hoping two of its drugs will lead to good fortune after experiencing disaster with lung cancer treatment ASA404.

GW Pharmaceuticals 31/08/2010

GW Pharmaceuticals has won approval from Health Canada for its cannabis-based Sativex product to treat spasticity caused by Multiple Sclerosis.

More Recommendations

Sectors

Vitesse Media Events